Study Of Relative Bioavailability/bioequivalence Of Two Formulations Of Valsartan In Healthy Volunteers For Both Sexes [estudo De Biodisponibilidade Relativa/bioequivalência De Duas Formulações De Valsartana Em Voluntários Sadios De Ambos Os Sexos]

The study was conducted to compare the bioavailability of two formulations of Valsartan 320 mg coated tablet (Valsartan of Aché S/A test formulation and Diovan® from Novartis Biociências S.A. reference formulation, Brazil) in 108 volunteers both sexes. This was an open, randomized, two-sequence, two-period, crossover single dose two treatments, in which a group of volunteers received the test formulation and the other reference formulation. Blood samples were obtained throughout a 48 hours interval. The Valsartan concentrations were determined by mass spectrometry (HPLC-MS-MS) using Losartan as internal standard. From the data obtained, calculate the following pharmacokinetic parameters: AUC0-t, AUC0-∞ and Cmax. The geometric mean of Valsartan/Diovan® 320 mg were 103.63% for AUC1-t, 102.72% for AUC0-∞ and 102.96% for Cmax. The 90% confidence intervals were 96.24%-111.59%, 95.64%-110.34% and 95.51%-110.98%, respectively. Since the confidence intervals 90% for Cmax and AUC0-t. was within the range 80%-125% proposed by the FDA and ANVISA (National Agency of Sanitary Surveillance in Brazil), it is concluded that the coated tablet of Valsartan 320 mg was bioequivalent to Diovan® coated tablet of 320 mg and thus the test product may be considered interchangeable in medical practice. © Copyright Moreira Jr. Editora.6911286290Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies (2002) Lancet, 360 (9349), pp. 1903-1913. , DOI 10.1016/S0140-6736(02)11911-8Lotufo, P.A., Stroke in Brazil: A neglected disease (2005) São Paulo Med J, 123, pp. 3-4Gus, I., Harzheim, E., Zaslavsky, C., Medina, C., Gus, M., Prevalence, Awareness, and Control of Systemic Arterial Hypertension in the State of Rio Grande do sul (2004) Arq Bras Cardiol, 83, pp. 429-433Matos, A.C., Ladeia, A.M., Assessment of Cardiovascular Risk Factors in a Rural Community in the Brazilian State of Bahia (2003) Arq Bras Cardiol, 81, pp. 297-302Passos, V., Hipertensão Arterial no Brasil: Estimativa de Prevalência a partir de estudos de base populacional (2006) Epidemiologia e Serviços de Saúde, 15, pp. 35-45Safar, M.E., Therapeutics trials and large arteries in hypertension (1988) Am Heart J, 115, pp. 702-710Penit, J., Faure, M., Jard, S., Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture (1983) Am J Physiol, 244, pp. 72-82Bunkenburg, B., Van Amelsvoort, T., Rogg, H., Wood, J.M., Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats (1992) Hypertension, 20, pp. 746-754Chung, Unger, T., Angiotensin II Receptor Blockade and End - Organ Protection (1999) Am J Hipertens, 12, pp. 150-156Geisterfer, A.A.T., Peach, M.J., Owens, G.K., Angiotensin II induces hypertrophy, not hyperplasia of cultured rat aortic smooth muscle cells (1988) Circ Res, 62, pp. 749-756Griffin, S.A., Brwon, W.C.B., MacPherson, F., MacGrath, J.C., Wilson, V.G., Korsgaard, N., Mulvany, M.J., Lever, A.F., Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism (1991) Hypertension, 17, pp. 626-635Griendling, K.K., Lassegue, B., Alexander, R.W., Angiotensin receptors and their therapeutic implications (1996) Annual Review of Pharmacology and Toxicology, 36, pp. 281-306Birkenhager, W.H., De Leeuw, P.W., Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension (1999) Journal of Hypertension, 17 (7), pp. 873-881. , DOI 10.1097/00004872-199917070-00002Burnier, M., Brunner, H.R., Angiotensin II receptor antagonists in Hypertension (1998) Kidney Int, 68, pp. 107-111Timmermans, P.B.M.W.M., Wong, P.C., Chiu, A.T., Herblin, W.F., Benfield, P., Carini, D.J., Lee, R.J., Smith, R.D., Angiotensin II receptors and angiotensin II receptor antagonists (1993) Pharmacological Reviews, 45 (2), pp. 205-251Burnier, M., Brunner, H.R., Angiotensin II receptor antagonists (2000) Lancet, 355, p. 637Markham, A., Goa, K.L., Valsartan. A review of its pharmacology and therapeutic use in essential hypertension (1997) Drugs, 54 (2), pp. 299-311Nie, J., Zhang, M., Fan, Y., Wen, Y., Xiang, B., Feng, Y.-Q., Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine (2005) Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 828 (1-2), pp. 62-69. , DOI 10.1016/j.jchromb.2005.09.015, PII S1570023205006537Flesch, G., Muller, P.., Lloyd, P., Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man (1997) European Journal of Clinical Pharmacology, 52 (2), pp. 115-120. , DOI 10.1007/s002280050259Criscione, L., Bradley, W.A., Buhlmayer, P., Whitebread, S., Glazer, R., Lloyd, P., Mueller, P., De Gasparo, M., Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist (1995) Cardiovascular Drug Reviews, 13 (3), pp. 230-250Oparil, S., Dyke, S., Harris, F., Kief, J., James, D., Hester, A., Fitzsimmons, S., The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension (1996) Clinical Therapeutics, 18 (5), pp. 797-810. , DOI 10.1016/S0149-2918(96)80040-3Criscione, L., De Gasparo, M., Buhlmayer, P., Whitebread, S., Ramjoue, H.-P.R., Wood, J., Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype (1993) British Journal of Pharmacology, 110 (2), pp. 761-771Waldmeier, F., Flesch, G., Muller, P., Winkler, T., Kriemler, H.-P., Buhlmayer, P., De Gasparo, M., Pharmacokinetics, disposition and biotransformation of [ 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose (1997) Xenobiotica, 27 (1), pp. 59-71. , DOI 10.1080/004982597240767Perez, M., Cardenas, W., Ramirez, G., Perez, M., Restrepo, P., A comparative, cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets (2006) Colombia Medica, 37 (2), pp. 114-120. , http://colombiamedica.univalle.edu.co/Vol37No2/html/cm37n2a4a.htmIsraili, Z.H., Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension (2000) J Hum Hypertens, 14, pp. 73-86Kannel, W.B., Blood pressure as a cardiovascular risk factor: Prevention and treatment (1996) Journal of the American Medical Association, 275 (20), pp. 1571-1576. , DOI 10.1001/jama.275.20.1571Padwal, R., Straus, S.E., McAlister, F.A., Evidence based management of hypertension: Cardiovascular risk factors and their effects on the decision to treat hypertension: Evidence based review (2001) British Medical Journal, 322 (7292), pp. 977-980Collins, R., MacMahon, S., Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease (1994) British Medical Bulletin, 50 (2), pp. 272-298Mion, D.J., Silva, V.G., Ortega, C.K., Nobre, F., The importance of the antihypertensive agent in the compliance to the treatment (2006) Rev Bras Hipertens, 13, pp. 55-58Pitt, B., Poole-Wilson, P.A., Segal, R., Martinez, F.A., Dickstein, K., Camm, A.J., Konstam, M.A., Thiyagarajan, B., Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II (2000) Lancet, 355 (9215), pp. 1582-1587Cohn, J.N., Tognoni, G., A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure (2001) N Engl J Med, 345, pp. 167-175. , on behalf of Valsartan Heart Failure Trial Investigator